A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET (NCT05482971)

🧪 Interventions in This Study

• Ropeginterferon alfa-2b-njft (P1101) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (34 Sites)

Showing the first 25 of 34 sites.

• University of Alabama at Birmingham — Birmingham, Alabama
• City of Hope National Medical Center — Duarte, California
• Marin Cancer Care — Greenbrae, California
• USC Norris Comprehensive Cancer Center — Los Angeles, California
• Yale University School of Medicine - Yale Cancer Center — New Haven, Connecticut
• Georgetown University Medical Center — Washington D.C., District of Columbia
• The Winship Cancer Institute Emory University — Atlanta, Georgia
• Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana
• Mercy Health - Paducah Medical Oncology and Hematology — Paducah, Kentucky
• Tulane University Medical Center — New Orleans, Louisiana
• Greater Baltimore Medical Center — Baltimore, Maryland
• Massachusetts General Hospital — Boston, Massachusetts
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Washington University School of Medicine - Division of Oncology — St Louis, Missouri
• Cancer Care Specialists — Reno, Nevada
• Astera HealthCare — East Brunswick, New Jersey
• John Theurer Cancer Center At Hackensack UMC — Hackensack, New Jersey
• Weill Medical College of Cornell University — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Stony Brook University Medical Center — Stony Brook, New York
• Montefiore Medical Center — The Bronx, New York
• University of North Carolina (UNC) - Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
• Duke University Medical Center — Durham, North Carolina
• East Carolina University — Greenville, North Carolina
• Regional Medical Oncology Center — Wilson, North Carolina

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Essential Thrombocythemia

• Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) — Glendale, Arizona
• Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance — Scottsdale, Arizona
• IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) — Miami, Florida
• A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) — Glendale, Arizona
• Ruxolitinib in Thrombocythemia and Polycythemia Vera — Boston, Massachusetts

Explore by condition: All Essential Thrombocythemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.